Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
HB

WKN: A2QJVC | ISIN: KYG4403H1002 | Ticker: 6XY
Tradegate
17.11.26 | 10:47
1,190 Euro
+1,71 % +0,020
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
HBM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
HBM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,1401,20018.11.
1,1401,20018.11.

Aktuelle News zur HBM HOLDINGS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03:17HBM HOLDINGS-B IND Application for New Drug LET003 Accepted1
01:00HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF IND APPLICATION FOR LET0031
MiHarbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company85CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...
► Artikel lesen
MiHBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - UPDATE ON CRHX-101 PROGRAM2
04.11.HBM HOLDINGS-B Repurchases 500,000 Shrs on Tue for HKD4.72M1
HBM HOLDINGS Aktie jetzt für 0€ handeln
03.11.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN3
27.10.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN2
23.10.HBM HOLDINGS-B Batoclimab Subcutaneous Injection Approved for Market Launch to Treat Generalized Myasthenia Gravis1
23.10.HBM HOLDINGS-B (02142): INSIDE INFORMATION ANNOUNCEMENT - NMPA APPROVAL OF BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTION) FOR THE TREATMENT OF GENERALIZED ...2
13.10.HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN-
21.09.HBM HOLDINGS-B (02142): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT AND THE 2026 INTERIM REPORT1
16.09.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - NONA BIOSCIENCES DEVELOPS THE WORLD'S FIRST LANGUAGE MODEL TRAINED ON FULLY HUMAN HEAVY-CHAIN-ONLY ANTIBODIES1
10.09.HBM HOLDINGS-B (02142): INTERIM REPORT 20261
09.09.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - IN RELATION TO SERIES A FINANCING OF THE COMPANY'S PARTNER SOLSTICE ONCOLOGY1
08.09.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE II INTERIM RESULTS AND INITIATION OF PHASE III STUDY OF HBM9378/WIN378 IN ASTHMA1
07.09.HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT2
02.09.HBM HOLDINGS-B (02142): SUPPLEMENTAL ANNOUNCEMENT - RESIGNATION OF EXECUTIVE DIRECTOR; APPOINTMENT OF EXECUTIVE DIRECTORS; AND CHANGE OF AUTHORIZED REPRESENTATIVE2
27.08.HBM Holdings Ltd H1 Profit Retreats6
27.08.HBM HOLDINGS-B (02142): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS2
27.08.HBM HOLDINGS-B (02142): RESIGNATION OF EXECUTIVE DIRECTOR; APPOINTMENT OF EXECUTIVE DIRECTORS; AND CHANGE OF AUTHORIZED REPRESENTATIVE3
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1